RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Taro Pharmaceutical Industries Stock

Taro Pharmaceutical Industries ROCE 2024

Taro Pharmaceutical Industries ROCE

0.01

Ticker

TARO

ISIN

IL0010827181

WKN

897505

In 2024, Taro Pharmaceutical Industries's return on capital employed (ROCE) was 0.01, a -83.58% increase from the 0.07 ROCE in the previous year.

Taro Pharmaceutical Industries Aktienanalyse

What does Taro Pharmaceutical Industries do?

Taro Pharmaceutical Industries Ltd. is a company that focuses on generic and specialized pharmaceutical products. The company was founded in Israel in 1950 and has since relocated its headquarters to Ireland. Taro Pharmaceutical has become one of the largest providers of generics and specialty drugs over the years due to its extensive experience, high-quality products, and ability to adapt to changing market conditions. The business model of Taro Pharmaceutical Industries is extremely simple. They offer affordable generic medications. The company's focus is on developing, manufacturing, and distributing generic products on the global market. Taro also has a wide range of specialty drugs, including dermatological and ophthalmology products. Taro Pharmaceutical Industries Ltd.'s business activities are divided into two divisions: Farmaceutica Taro, which specializes in the development, manufacturing, and distribution of generics and specialty drugs, and Taro Research & Development Center, which focuses on researching and developing new medications and generic products. Taro Pharmaceutical Industries Ltd. offers a wide range of products, including tablets, ointments, and eye drops. The company provides a variety of products in various therapeutic areas such as dermatology, cardiology, urology, gynecology, neurology, pediatrics, gastroenterology, and infectious diseases. The dermatological products of Taro Pharmaceutical, such as Clobetasol Propionate Cream and Lidocaine, are known for their effectiveness in skincare. With its eye products like Dorzolamide and Timolol Maleate Ophthalmic Solution, the company focuses on the ophthalmology field. Taro also produces medications that help with cardiovascular diseases, such as Amlodipine and Enalapril. Taro Pharmaceutical Industries Ltd. was founded in 1950 by chemist George Rosenberg and his partner Leo Ringer in Haifa, Israel. Manufacturing of pharmaceutical ingredients for drug production began in 1951. The company has been focused on growth since its inception and has built a strong reputation for its production quality. In 1969, Taro Pharmaceutical went public with a market capitalization of approximately 8 million US dollars. Over the years, the company expanded its portfolio and grew rapidly through acquisitions of other companies and expansion into international locations such as Canada, Switzerland, Mexico, Spain, and Italy. Taro Pharmaceutical was sold to Italian pharma company Ariston in 1993 and acquired by Indian pharma company Sun Pharmaceutical Industries in 2013. The company's headquarters is now in Dublin, Ireland, and it produces for markets worldwide, including North America, Europe, Asia, Australia, and South America. In conclusion, Taro Pharmaceutical Industries is one of the leading companies in the generic production field and has become a strong player in the specialized pharmaceutical products sector. The company has proven its expertise in research and development, manufacturing, and distribution of sought-after products. With the global demand for medications expected to continue rising, a company like Taro, which offers sustainable and affordable preventive solutions, plays an important role in the healthcare industry and will continue to do so in the future. Taro Pharmaceutical Industries ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Taro Pharmaceutical Industries's Return on Capital Employed (ROCE)

Taro Pharmaceutical Industries's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Taro Pharmaceutical Industries's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Taro Pharmaceutical Industries's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Taro Pharmaceutical Industries’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Taro Pharmaceutical Industries stock

What is the ROCE (Return on Capital Employed) of Taro Pharmaceutical Industries this year?

The ROCE of Taro Pharmaceutical Industries is 0.01 undefined this year.

How has the ROCE (Return on Capital Employed) of Taro Pharmaceutical Industries developed compared to the previous year?

The ROCE of Taro Pharmaceutical Industries has increased by -83.58% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Taro Pharmaceutical Industries?

A high Return on Capital Employed (ROCE) indicates that Taro Pharmaceutical Industries has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Taro Pharmaceutical Industries?

A low ROCE (Return on Capital Employed) can indicate that Taro Pharmaceutical Industries has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Taro Pharmaceutical Industries impact the company?

An increase in the ROCE of Taro Pharmaceutical Industries can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Taro Pharmaceutical Industries affect the company?

A decrease in ROCE of Taro Pharmaceutical Industries can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Taro Pharmaceutical Industries?

Some factors that can affect Taro Pharmaceutical Industries's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Taro Pharmaceutical Industries so important for investors?

The ROCE of Taro Pharmaceutical Industries is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Taro Pharmaceutical Industries take to improve the ROCE?

To improve the ROCE, Taro Pharmaceutical Industries can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Taro Pharmaceutical Industries pay?

Over the past 12 months, Taro Pharmaceutical Industries paid a dividend of 12.86 USD . This corresponds to a dividend yield of about 29.93 %. For the coming 12 months, Taro Pharmaceutical Industries is expected to pay a dividend of 6.95 USD.

What is the dividend yield of Taro Pharmaceutical Industries?

The current dividend yield of Taro Pharmaceutical Industries is 29.93 %.

When does Taro Pharmaceutical Industries pay dividends?

Taro Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries paid dividends every year for the past 1 years.

What is the dividend of Taro Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 6.95 USD are expected. This corresponds to a dividend yield of 16.17 %.

In which sector is Taro Pharmaceutical Industries located?

Taro Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Taro Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Taro Pharmaceutical Industries from 12/28/2018 amounting to 12.86 USD, you needed to have the stock in your portfolio before the ex-date on 12/10/2018.

When did Taro Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/28/2018.

What was the dividend of Taro Pharmaceutical Industries in the year 2023?

In the year 2023, Taro Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Taro Pharmaceutical Industries pay out the dividend?

The dividends of Taro Pharmaceutical Industries are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Taro Pharmaceutical Industries

Our stock analysis for Taro Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Taro Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.